How peptide technology has improved costs and outcomes in patients with heart failure

References

• Hobbs FD, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J. 2007;28:1128–1134.
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–1146.
   PubMed Web of Science ®Google Scholar
• Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368–376.
   PubMed Web of Science ®Google Scholar
• Parissis J, Athanasakis K, Farmakis D, et al. Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. Int J Cardiol. 2015;180:46–49.
   PubMed Web of Science ®Google Scholar
• Soundarraj D, Singh V, Satija V, et al. Containing the cost of heart failure management: a focus on reducing readmissions. Card Electrophysiol Clin. 2015;7:577–584.
   PubMedGoogle Scholar
• Rehman SU, Januzzi JL. Natriuretic peptide testing in primary care. Curr Cardiol Rev. 2008;4:300–308.
   PubMedGoogle Scholar
• Goode KM, Clark AL, Cleland JG. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width. Int J Cardiol. 2008;130:426–437.
   PubMed Web of Science ®Google Scholar
• Don-Wauchope AC, Santaguida PL, Oremus M, et al. Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review. Heart Fail Rev. 2014;19:521–540.
   PubMed Web of Science ®Google Scholar
• Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. Bmj. 2015;350:h910.
   PubMed Web of Science ®Google Scholar
• Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–366.
   PubMedGoogle Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
   Google Scholar
• Dokainish H, Zoghbi WA, Ambriz E, et al. Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol. 2006;97:400–403.
   PubMed Web of Science ®Google Scholar
• Siebert U, Januzzi JL Jr, Beinfeld MT, et al. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800–805.
   PubMed Web of Science ®Google Scholar
• Collinson PO. The cost effectiveness of B-Type natriuretic peptide measurement in the primary care setting-a UK perspective. Congest Heart Fail. 2006;12:103–107.
   PubMedGoogle Scholar
• Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:1081–1087.
   PubMedGoogle Scholar
• Lim TK, Dwivedi G, Hayat S. Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure. Echocardiography. 2007;24:228–236.
   PubMed Web of Science ®Google Scholar
• Scott MA, Price CP, Cowie MR, et al. Cost-consequences analysis of natriuretic peptide assays to refute symptomatic heart failure in primary care. Br J Cardiol. 2008;15:199–204, 6.
   Google Scholar
• Adlbrecht C, Huelsmann M, Berger R. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Invest. 2011;41:315–322.
   PubMed Web of Science ®Google Scholar
• Moertl D, Steiner S, Coyle D, et al. Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care. 2013;29:3–11.
   PubMed Web of Science ®Google Scholar
• Sanders-van Wijk S, van Asselt AD, Rickli H, et al. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of intensified versus standard medical therapy in elderly patients with congestive heart failure). JACC Heart Fail. 2013;1:64–71.
   PubMed Web of Science ®Google Scholar
• Laramée P, Wonderling D, Swain S, et al. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart. 2013;99:267–271.
   PubMed Web of Science ®Google Scholar
• Ledwidge MT, O’Connell E, Gallagher J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent’s screening TO prevent heart failure) study. Eur J Heart Fail. 2015;17:672–679.
   PubMed Web of Science ®Google Scholar
• Aspromonte N, Ceci V, Chiera A, et al. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem. 2006;52:1802–1808.
   PubMed Web of Science ®Google Scholar
• Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103–3110.
   PubMed Web of Science ®Google Scholar
• Hawkins RC, Chung KN. B-type natriuretic peptide testing is associated with reduced cost in patients with secondary diagnosis of heart failure. Clin Chim Acta. 2007;377:276–278.
   PubMed Web of Science ®Google Scholar
• Goode KM, Clark AL, Bristow JA, et al. Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: a cost-benefit analysis. Eur J Heart Fail. 2007;9:1186–1195.
   PubMed Web of Science ®Google Scholar
• Rutten JH, Steyerberg EW, Boomsma F, et al. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. Am Heart J. 2008;156:71–77.
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N, Carbonieri E, et al. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol. 2008;126:400–406.
   PubMed Web of Science ®Google Scholar
• Behnes M, Brueckmann M, Ahmad-Nejad P, et al. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol. 2009;135:165–174.
   PubMed Web of Science ®Google Scholar
• Breidthardt T, Noveanu M, Cayir S, et al. The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. Int J Cardiol. 2009;136:193–199.
   PubMed Web of Science ®Google Scholar
• Noveanu M, Pargger H, Breidthardt T, et al. Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. Eur J Heart Fail. 2011;13:154–162.
   PubMed Web of Science ®Google Scholar
• Burri E, Hochholzer K, Arenja N, et al. B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. J Intern Med. 2012;272:504–513.
   PubMed Web of Science ®Google Scholar
• Chapman AR, Leslie SJ, Walker SW, et al. Potential costs of B-type natriuretic peptide for the identification of people with heart failure in primary care in Scotland - a pilot study. J R Coll Physicians Edinb. 2015;45:27–32.
   PubMedGoogle Scholar
• Maisel A, Xue Y, Greene SJ, et al. The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. J Card Fail. 2015;21:233–239.
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832:2442–2450.
   PubMed Web of Science ®Google Scholar
• Grewal J, Chandavimol M, Ignaszewski A. B-type natriuretic peptide: a new marker for congestive heart failure. BCMJ. 2004;46:24–29.
   Google Scholar
• Krupicka J, Janota T, Kasalová Z, et al. Natriuretic peptides: physiology, pathophysiology and clinical use in heart failure. Physiol Res. 2009;58:171–177.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentaration; impact of age and gender. J Am CollCardiol. 2002;40:976–982.
   Web of Science ®Google Scholar
• Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611–617.
   PubMed Web of Science ®Google Scholar